Should I buy or sell Zymeworks stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ZYME shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZYME, but not buy additional shares or sell existing shares. View ZYME analyst ratings or view top-rated stocks .

What is Zymeworks' stock price target for 2024?

1 analysts have issued twelve-month target prices for Zymeworks' shares. Their ZYME share price targets range from $8.00 to $19.00. On average, they predict the company's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 66.9% from the stock's current price. View analysts price targets for ZYME or view top-rated stocks among Wall Street analysts .

How have ZYME shares performed in 2024?

Zymeworks' stock was trading at $10.39 at the beginning of 2024. Since then, ZYME shares have decreased by 13.5% and is now trading at $8.99. View the best growth stocks for 2024 here .

When is Zymeworks' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our ZYME earnings forecast .

How can I listen to Zymeworks' earnings call?

Zymeworks will be holding an earnings conference call on Thursday, May 2nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link .

How were Zymeworks' earnings last quarter?

Zymeworks Inc. (NYSE:ZYME) released its quarterly earnings data on Wednesday, March, 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.39) by $0.19. The business earned $16.93 million during the quarter, compared to analysts' expectations of $18.32 million. Zymeworks had a negative net margin of 156.12% and a negative trailing twelve-month return on equity of 26.20%.

What ETF holds Zymeworks' stock?

Invesco Russell 2000 Dynamic Multifactor ETF holds 165,345 shares of ZYME stock, representing 0.41% of its portfolio.

What is Ali Tehrani's approval rating as Zymeworks' CEO?

9 employees have rated Zymeworks Chief Executive Officer Ali Tehrani on Glassdoor.com . Ali Tehrani has an approval rating of 100% among the company's employees. This puts Ali Tehrani in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Zymeworks to a friend.

What other stocks do shareholders of Zymeworks own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zymeworks investors own include Advanced Micro Devices (AMD) , Gilead Sciences (GILD) , Just Energy Group (JE) , NVIDIA (NVDA) , Just Energy Group (JE) , PayPal (PYPL) , Alibaba Group (BABA) , Cronos Group (CRON) , CRISPR Therapeutics (CRSP) and Tesla (TSLA) .

When did Zymeworks IPO?

Zymeworks (ZYME) raised $65 million in an initial public offering (IPO) on Friday, April 28th 2017. The company issued 4,500,000 shares at $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity acted as the underwriters for the IPO and Cormark Securities was co-manager.

How do I buy shares of Zymeworks?

Shares of ZYME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:ZYME

Zymeworks (ZYME) Stock Price, News & Analysis

→ Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad)

Free ZYME Stock Alerts

$9.03

-0.06 (-0.66%)

(As of 01:03 PM ET)

Compare

Today's Range: $8.91
▼
$9.10
50-Day Range: $9.09
▼
$12.90
52-Week Range: $6.01
▼
$13.14

Volume: 97,748 shs
Average Volume: 561,187 shs
Market Capitalization: $637.25 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.00

Get Zymeworks alerts:

Zymeworks MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 66.9% Upside
$15.00 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.06
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.04) to ($0.37) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.91 out of 5 stars

Medical Sector

836th out of 930 stocks

Pharmaceutical Preparations Industry

390th out of 429 stocks

3.0

Analyst's Opinion

Consensus Rating
Zymeworks has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Zymeworks has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for ZYME.

0.0

Dividend Strength

Dividend Yield
Zymeworks does not currently pay a dividend.
Dividend Growth
Zymeworks does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ZYME.

1.1

News and Social Media Coverage

News Sentiment
Zymeworks has a news sentiment score of -0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Zymeworks this week, compared to 2 articles on an average week.
Search Interest
Only 4 people have searched for ZYME on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Zymeworks to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Zymeworks insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.22% of the stock of Zymeworks is held by insiders.
Percentage Held by Institutions
92.89% of the stock of Zymeworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Zymeworks are expected to grow in the coming year, from ($1.04) to ($0.37) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Zymeworks is -5.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Zymeworks is -5.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Zymeworks has a P/B Ratio of 1.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Wall Street Star

This Apple-like Innovator is Revolutionizing Healthcare

AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.

Click here to learn more about the booming eHealth industry

About Zymeworks Stock (NYSE:ZYME)

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

ZYME Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ZYME Stock News Headlines

April 12, 2024 | markets.businessinsider.com

Maintaining Hold on Zymeworks: ZW191’s Potential Amidst Competitive and Regulatory Hurdles

April 12, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME

April 16, 2024 | Crypto Swap Profits (Ad)

Did You Get Your Free Bitcoin Yet?

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

April 11, 2024 | globenewswire.com

Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

April 8, 2024 | globenewswire.com

Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting

April 4, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME

April 4, 2024 | morningstar.com

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Zymeworks Inc. (ZYME)

April 2, 2024 | stockhouse.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME

April 16, 2024 | Crypto Swap Profits (Ad)

Did You Get Your Free Bitcoin Yet?

March 28, 2024 | finanznachrichten.de

Zymeworks Inc.: Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors

March 28, 2024 | globenewswire.com

Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors

March 27, 2024 | globenewswire.com

Zymeworks Announces Participation in Upcoming Investor Conferences

March 13, 2024 | markets.businessinsider.com

Analysts’ Top Healthcare Picks: Zymeworks (ZYME), 89bio (ETNB)

March 12, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Zymeworks Amid Positive HERIZON Study Outlook and Robust Commercial Prospects of Zanidatamab

March 11, 2024 | markets.businessinsider.com

Hold Rating on Zymeworks Amidst Pipeline Adjustments and Clinical Validation Awaited

March 8, 2024 | investorplace.com

Next-Gen Winners: 7 Tech Stocks Set to Dominate the Decade

March 7, 2024 | finanznachrichten.de

Zymeworks Inc.: Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results

March 7, 2024 | finance.yahoo.com

Zymeworks Inc. (NYSE:ZYME) Q4 2023 Earnings Call Transcript

March 7, 2024 | finance.yahoo.com

Zymeworks Inc (ZYME) Reports Financial Results for Q4 and Full Year 2023

March 7, 2024 | investorplace.com

ZYME Stock Earnings: Zymeworks Beats EPS, Beats Revenue for Q4 2023

March 6, 2024 | seekingalpha.com

Zymeworks Inc. 2023 Q4 - Results - Earnings Call Presentation

March 6, 2024 | msn.com

Zymeworks Q4 2023 Earnings Preview

March 6, 2024 | globenewswire.com

Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results

March 5, 2024 | globenewswire.com

Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting

March 5, 2024 | ca.finance.yahoo.com

ZYME Apr 2024 7.500 call

March 5, 2024 | ca.finance.yahoo.com

ZYME Oct 2024 15.000 call

March 5, 2024 | finance.yahoo.com

ZYME Mar 2024 20.000 call

See More Headlines

Receive ZYME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zymeworks and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/06/2024
Today: 4/16/2024
Next Earnings (Confirmed): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NYSE:ZYME
Previous Symbol: NASDAQ:ZYME
CUSIP: N/A
CIK: 1403752
Web: www.zymeworks.com
Phone: (302) 274-8744
Fax: 604-737-7077
Employees: 272
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $15.00
High Stock Price Target: $19.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +66.9%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.74)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-118,670,000.00
Net Margins: -156.12%
Pretax Margin: -156.87%
Return on Equity: -26.20%
Return on Assets: -20.29%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.41
Quick Ratio: 7.41

Sales & Book Value

Annual Sales: $76.01 million
Price / Sales: 8.35
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.63 per share
Price / Book: 1.36

Miscellaneous

Outstanding Shares: 70,570,000
Free Float: 69,707,000
Market Cap: $634.42 million
Optionable: Optionable
Beta: 1.14

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. Kenneth H. Galbraith C.A. (Age 61)
CEO & Chairman of the Board
Comp: $1.04M
Dr. Christopher Astle Ph.D. (Age 43)
Senior VP & CFO
Comp: $682.22k
Dr. Paul Moore Ph.D. (Age 56)
Chief Scientific Officer
Comp: $872.67k
Mr. Mark Hollywood (Age 54)
Executive VP and Head of Technical & Manufacturing Operations
Mr. Daniel Dex J.D.
Ph.D., Senior VP, Corporate Secretary & General Counsel
Diana Papove
Senior Manager of Corporate Communications
Dr. Lindsey Foulkes B.Sc.
Ph.D., Vice President of Corporate Development
Ms. Laura O'Connor
Vice President of Human Resources & DEI
Dr. Jeffrey Smith M.D.
Executive VP & Chief Medical Officer
Dr. Josemund Menezes MBBS
Managing Director of Early-Stage Development for Asia Pacific

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ZYME Stock Analysis - Frequently Asked Questions

Should I buy or sell Zymeworks stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ZYME shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZYME, but not buy additional shares or sell existing shares.
View ZYME analyst ratings or view top-rated stocks.
What is Zymeworks' stock price target for 2024?: 1 analysts have issued twelve-month target prices for Zymeworks' shares. Their ZYME share price targets range from $8.00 to $19.00. On average, they predict the company's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 66.9% from the stock's current price.
View analysts price targets for ZYME or view top-rated stocks among Wall Street analysts.
How have ZYME shares performed in 2024?: Zymeworks' stock was trading at $10.39 at the beginning of 2024. Since then, ZYME shares have decreased by 13.5% and is now trading at $8.99.
View the best growth stocks for 2024 here.
When is Zymeworks' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ZYME earnings forecast.
How can I listen to Zymeworks' earnings call?: Zymeworks will be holding an earnings conference call on Thursday, May 2nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.
How were Zymeworks' earnings last quarter?: Zymeworks Inc. (NYSE:ZYME) released its quarterly earnings data on Wednesday, March, 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.39) by $0.19. The business earned $16.93 million during the quarter, compared to analysts' expectations of $18.32 million. Zymeworks had a negative net margin of 156.12% and a negative trailing twelve-month return on equity of 26.20%.

What ETF holds Zymeworks' stock?: Invesco Russell 2000 Dynamic Multifactor ETF holds 165,345 shares of ZYME stock, representing 0.41% of its portfolio.
What is Ali Tehrani's approval rating as Zymeworks' CEO?: 9 employees have rated Zymeworks Chief Executive Officer Ali Tehrani on Glassdoor.com. Ali Tehrani has an approval rating of 100% among the company's employees. This puts Ali Tehrani in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Zymeworks to a friend.
What other stocks do shareholders of Zymeworks own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Zymeworks investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Just Energy Group (JE), NVIDIA (NVDA), Just Energy Group (JE), PayPal (PYPL), Alibaba Group (BABA), Cronos Group (CRON), CRISPR Therapeutics (CRSP) and Tesla (TSLA).
When did Zymeworks IPO?: Zymeworks (ZYME) raised $65 million in an initial public offering (IPO) on Friday, April 28th 2017. The company issued 4,500,000 shares at $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity acted as the underwriters for the IPO and Cormark Securities was co-manager.
How do I buy shares of Zymeworks?: Shares of ZYME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:ZYME) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Zymeworks (ZYME) Stock Price, News & Analysis

Zymeworks MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Zymeworks Stock (NYSE:ZYME)

ZYME Stock Price History

ZYME Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ZYME Stock Analysis - Frequently Asked Questions

Overall MarketRank^™